Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Vadasac 50 Sacubitril & Valsartan Tablets
Vadasac 50, provided by Lexaro Healthcare, contains 50 mg of Sacubitril and Valsartan in each tablet. This combination therapy is specifically formulated to manage heart failure with reduced ejection fraction (HFrEF), offering a dual mechanism of action to improve heart function and reduce symptoms.
Uses of Vadasac 50 Sacubitril & Valsartan Tablets
Vadasac 50 is primarily prescribed for:
Managing heart failure with reduced ejection fraction (HFrEF).
Reducing the risk of cardiovascular death and hospitalization due to heart failure.
Improving exercise capacity and overall quality of life in patients with HFrEF.
Providing an effective alternative to traditional heart failure treatments.
Benefits of Vadasac 50 Sacubitril & Valsartan Tablets
Combines Sacubitril and Valsartan for enhanced efficacy in managing heart failure.
Reduces the risk of cardiovascular death and hospitalizations related to heart failure.
Improves symptoms of heart failure, including shortness of breath and fatigue.
Helps in improving exercise tolerance and overall quality of life.
Convenient tablet formulation for easy administration.
Well-tolerated with a favorable safety profile when used as directed.
Mechanism of Action of Vadasac 50 Sacubitril & Valsartan Tablets
Sacubitril is a neprilysin inhibitor that works by increasing the levels of natriuretic peptides and other vasoactive peptides. This leads to vasodilation, reduced fluid retention, and improved heart function. Sacubitril helps to decrease blood pressure and reduce strain on the heart.
Valsartan is an angiotensin II receptor blocker (ARB) that inhibits the action of angiotensin II, a hormone that causes vasoconstriction and increases blood pressure. By blocking this hormone, Valsartan reduces blood pressure, decreases the workload on the heart, and helps to manage symptoms of heart failure.